Caribou Biosciences, Inc. revenue breakdown overview

Caribou Biosciences, Inc. revenue for the last year amounted to 9.99 M USD, the most of which — 9.99 M USD — came from its highest performing source at the moment, Allogeneic Chimeric Antigen Receptor - T Cell Therapies, the year earlier bringing 34.48 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Caribou Biosciences, Inc. 9.27 M USD, and the year before that — 32.77 M USD.